Antibodies Targeting EMT
Technical Report,30 Sep 2014,29 Sep 2015
The Scripps Research Institute La Jolla United States
Pagination or Media Count:
Monoclonal antibodies are drugs that can specifically bind targets present on tumor cells. The highly aggressive triple-negative subtype of breast cancer does not have specific antibody drugs like Herceptin, and there is considerable need for targeted therapeutics and diagnostic biomarkers. We have developed a new technique allowing for discovery of new antibodies that disrupt a key process in cancer progression termed epithelial to mesenchymal transition or EMT. This process is important in several cancers, but is particularly associated with triple-negative breast cancer. We have applied our technology to identify unique antibodies that inhibit EMT and are now characterizing the antibodies to determine their targets on the cell. The newly discovered antibodies will then be engineered for utility as new highly specific drugs and diagnostics in preclinical experiments. This research could provide a new class of antibody therapeutic and diagnostic for triple-negative disease, identify new drug targets or pathways in cancer cells and make a major impact on breast cancer.